Clinical Trial Update: Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy [Phase 2]

View source ↗

Summary

A Phase 2 study of pamrevlumab (FG-3019) in subjects with type 2 diabetes mellitus and diabetic kidney disease on ACE inhibitors or ARBs has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Kidney Disease
• Diabetic Nephropathy
• Type 2 Diabetes Mellitus

Drugs mentioned

• pamrevlumab (FG-3019) (pamrevlumab)

Snippet

Sponsor: Kyntra Bio | Conditions: Type 2 Diabetes Mellitus, Diabetic Nephropathy | Phase 2 | Status: TERMINATED